News · Exor N.V.
Exor: its bioMérieux stake would rise from 3.87% to 8.53% directly, from about 9.9% to 11.3% look-through
Exor would receive bioMérieux shares in exchange for part of its Institut Mérieux shares: its direct stake would rise from 3.87% to 8.53%, its stake in Institut Mérieux would fall from 10.0% at 30 June to 5.02%. Counting what it holds through Institut Mérieux, its share of bioMérieux would go from about 9.9% to 11.3% (Opulion calculation). The exchange would mainly change the form of the holding, less unlisted and more listed (Opulion view).
Why it matters for Exor shareholders: at 30 June, Exor carried Institut Mérieux at €680m, against €956m at 31 December 2025, a fall it attributes to the share prices of bioMérieux, 69% of Institut Mérieux's portfolio, and Transgene, partly offset by Moderna. Its direct, listed stake in bioMérieux was worth €298m, against €478m. The two holdings come to €978m, 2.7% of gross asset value of €35,768m (Opulion calculation). The same company weighs on two of Exor's holdings, and the exchange would enlarge the listed one at the expense of the unlisted one.
The mechanism is a reduction of Institut Mérieux's share capital: Exor would hand over part of its Institut Mérieux shares and receive bioMérieux shares in exchange. Institut Mérieux would remain the majority shareholder, with 55.24% of the capital and 68.67% of the voting rights of bioMérieux. Before the transaction, it would hold about 59.90% of the capital, if the 4.66 points passed to Exor (8.53 − 3.87) all came from it (Opulion calculation, consistent with the stake "close to 60%" that Institut Mérieux announced on 6 May). The release publishes no price, exchange ratio or number of shares. Exor and the Mérieux family state that they do not intend to act in concert with respect to bioMérieux.
The look-through stake adds the direct holding to the share held through Institut Mérieux (Opulion calculation). Before: 3.87% directly, plus 10.0% of 59.90%, or about 9.9%. After: 8.53% directly, plus 5.02% of 55.24%, or about 11.3%. Opulion assumption: Exor still holds 10.0% of Institut Mérieux's economic rights, its latest published figure (30 June 2026). The direct stake would more than double, the look-through stake would gain about 1.4 points. In return, Exor would reduce its share of Institut Mérieux's other assets, including Transgene and Mérieux NutriSciences. Our analysis of 31 August placed the 2025 strengthening of bioMérieux in Exor's first route: reinforcing companies it already owns.
A director for Exor
bioMérieux's board is expected to propose his appointment at its next annual general meeting. He currently sits on its board as a non-voting observer.
Completion
After the creditor objection period and approval by Institut Mérieux's shareholders.
Price and exchange ratio
The release says neither how many Institut Mérieux shares Exor gives up, nor at what value.
For Exor shareholders, three facts will decide. In December, the expected completion, after the creditor objection period and the vote of Institut Mérieux's shareholders. Then Exor's 2026 annual report, which would show the value at which both holdings are carried after the exchange. The third would come later: the vote of bioMérieux's next general meeting on the director its board is expected to propose to represent Exor.
Sources
- Exor and Institut Mérieux, Exor to raise its stake in bioMérieux, 19 November 2026 · Exor N.V. · Nov 19, 2026
- Institut Mérieux, purchase of an additional 1% stake in bioMérieux, 6 May 2026 · Institut Mérieux · May 6, 2026
- Exor, 2026 first-half report · Exor N.V. · Sep 22, 2026
- Exor, Institut Mérieux page (figures at 30 June 2026) · Exor N.V. · Nov 19, 2026
Share this article